HRMY
Harmony Biosciences Holdings Inc

17,085
Mkt Cap
$1.92B
Volume
897,991.00
52W High
$40.93
52W Low
$25.52
PE Ratio
10.49
HRMY Fundamentals
Price
$33.39
Prev Close
$33.31
Open
$33.25
50D MA
$29.63
Beta
0.85
Avg. Volume
849,587.04
EPS (Annual)
$2.51
P/B
2.30
Rev/Employee
$2.67M
Loading...
Loading...
News
all
press releases
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by LSV Asset Management
LSV Asset Management grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 24.6% during the second quarter, according to the company in its most recent Form...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2...
Business Wire·1d ago
News Placeholder
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare...
Business Wire·2d ago
News Placeholder
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Rating of "Moderate Buy" by Brokerages
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the company...
MarketBeat·3d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Acquires 134,649 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Connor Clark & Lunn Investment Management Ltd. increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 117.9% in the second quarter, according to its most recent...
MarketBeat·7d ago
News Placeholder
Research Analysts Set Expectations for HRMY FY2025 Earnings
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings estimates for Harmony Biosciences in a research report issued...
MarketBeat·12d ago
News Placeholder
Mizuho Issues Positive Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price
Mizuho boosted their price target on Harmony Biosciences from $36.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday...
MarketBeat·13d ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -5.43% and +4.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX. These results were driven by the highest...
Business Wire·16d ago
News Placeholder
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·22d ago

Latest HRMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.